Vanda Pharmaceuticals Inc.
As of Oct 22, 2026, Vanda Pharmaceuticals is in Stage 4, the downtrend phase, now in week 17 (since Jun 26, 2026). It closed at $4.05, 57.6% below its 52-week high and below its 200-day average, which is falling.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is VNDA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
VNDA among Biotechnology256th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …256 | VNDA | Stage 4 · wk 17 | 37 | −19.6% |
Vanda Pharmaceuticals: quick answers
What stage is Vanda Pharmaceuticals in?
As of Oct 22, 2026, Vanda Pharmaceuticals (VNDA) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 26, 2026 and is in week 17. What the four stages mean
Is Vanda Pharmaceuticals in an uptrend?
No. Vanda Pharmaceuticals is in a Stage 4 downtrend. It trades 36.0% below its 200-day average, which is falling.
How far is Vanda Pharmaceuticals from its 52-week high?
Vanda Pharmaceuticals closed at $4.05 on Oct 22, 2026, 57.6% below its 52-week high of $9.56. Its 52-week low is $4.03.
How has Vanda Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Vanda Pharmaceuticals is down 23.4% over the past year and down 50.9% so far in 2026.
Which sector and industry is Vanda Pharmaceuticals in?
Vanda Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.